Literature DB >> 26233847

Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats.

Jun-Xian Yu1, Sukesh Voruganti2, Dan-Dan Li3, Jiang-Jiang Qin2, Subhasree Nag4, Su Xu5, Sadanandan E Velu5, Wei Wang6, Ruiwen Zhang7.   

Abstract

We have recently designed and synthesized several novel iminoquinone anticancer agents that have entered preclinical development for the treatment of human cancers. Herein we developed and validated a quantitative HPLC-MS/MS analytical method for one of the lead novel anticancer makaluvamine analog, TCBA-TPQ, and conducted a pharmacokinetic study in laboratory rats. Our results indicated that the HPLC-MS/MS method was precise, accurate, and specific. Using this method, we carried out in vitro and in vivo evaluations of the pharmacological properties of TCBA-TPQ and plasma pharmacokinetics in rats. Our results provide a basis for future preclinical and clinical development of this promising anticancer marine analog.
Copyright © 2015 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  LC-MS/MS; Makaluvamine analogs; Pharmacokinetics; Rat plasma; TCBA-TPQ

Mesh：

Substances：

Year:  2015        PMID： 26233847      PMCID： PMC4716806          DOI： 10.1016/S1875-5364(15)30051-0

Source DB:  PubMed          Journal:  Chin J Nat Med        ISSN： 1875-5364


  25 in total

Review 1.  The odyssey of marine pharmaceuticals: a current pipeline perspective.

Authors:  Alejandro M S Mayer; Keith B Glaser; Carmen Cuevas; Robert S Jacobs; William Kem; R Daniel Little; J Michael McIntosh; David J Newman; Barbara C Potts; Dale E Shuster
Journal:  Trends Pharmacol Sci       Date:  2010-04-02       Impact factor: 14.819

2.  Development and validation of an HPLC method for quantitation of BA-TPQ, a novel iminoquinone anticancer agent, and an initial pharmacokinetic study in mice.

Authors:  Haibo Li; Scharri J Ezell; Xiangrong Zhang; Wei Wang; Hongxia Xu; Elizabeth R Rayburn; Xu Zhang; Evrim Gurpinar; Xinyi Yang; Charnell I Sommers; Sadanandan E Velu; Ruiwen Zhang
Journal:  Biomed Chromatogr       Date:  2010-09-15       Impact factor: 1.902

3.  Simultaneous determination of isoniazid, rifampicin, levofloxacin in mouse tissues and plasma by high performance liquid chromatography-tandem mass spectrometry.

Authors:  Ping-Fei Fang; Hua-Lin Cai; Huan-De Li; Rong-Hua Zhu; Qin-You Tan; Wei Gao; Ping Xu; Yi-Ping Liu; Wen-Yuan Zhang; Yong-Chang Chen; Feng Zhang
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-07-03       Impact factor: 3.205

4.  Synthesis and in vitro anti-lung cancer activity of novel 1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogs.

Authors:  Dwayaja H Nadkarni; Feng Wang; Wei Wang; Elizabeth R Rayburn; Scharri J Ezell; Srinivasan Murugesan; Sadanandan E Velu; Ruiwen Zhang
Journal:  Med Chem       Date:  2009-05       Impact factor: 2.745

5.  Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent.

Authors:  Scharri J Ezell; Haibo Li; Hongxia Xu; Xiangrong Zhang; Evrim Gurpinar; Xu Zhang; Elizabeth R Rayburn; Charnell I Sommers; Xinyi Yang; Sadanandan E Velu; Wei Wang; Ruiwen Zhang
Journal:  Mar Drugs       Date:  2010-07-13       Impact factor: 5.118

6.  A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action.

Authors:  Wei Wang; Elizabeth R Rayburn; Sadanandan E Velu; Deng Chen; Dwayaja H Nadkarni; Srinivasan Murugesan; Dongquan Chen; Ruiwen Zhang
Journal:  Breast Cancer Res Treat       Date:  2009-11-21       Impact factor: 4.872

7.  FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer.

Authors:  Feng Wang; Scharri J Ezell; Yong Zhang; Wei Wang; Elizabeth R Rayburn; Dwayaja H Nadkarni; Srinivasan Murugesan; Sadanandan E Velu; Ruiwen Zhang
Journal:  Invest New Drugs       Date:  2009-03-10       Impact factor: 3.850

8.  In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues.

Authors:  Wei Wang; Elizabeth R Rayburn; Sadanandan E Velu; Dwayaja H Nadkarni; Srinivasan Murugesan; Ruiwen Zhang
Journal:  Clin Cancer Res       Date:  2009-05-15       Impact factor: 12.531

9.  Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action.

Authors:  Tao Chen; Yi Xu; He Guo; Yanling Liu; Pingting Hu; Xinying Yang; Xiaoguang Li; Shichao Ge; Sadanandan E Velu; Dwayaja H Nadkarni; Wei Wang; Ruiwen Zhang; Hui Wang
Journal:  PLoS One       Date:  2011-06-06       Impact factor: 3.240

10.  Preclinical evaluation of anticancer efficacy and pharmacological properties of FBA-TPQ, a novel synthetic makaluvamine analog.

Authors:  Xiangrong Zhang; Hongxia Xu; Xu Zhang; Sukesh Voruganti; Srinivasan Murugesan; Dwayaja H Nadkarni; Sadanandan E Velu; Ming-Hai Wang; Wei Wang; Ruiwen Zhang
Journal:  Mar Drugs       Date:  2012-05-23       Impact factor: 6.085
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.